Uncategorized
CanVeer Files International PCT Patent Application Supporting Global IP Strategy for Chronic Respiratory Conditions
Mississauga, CanadaCanVeer Biopharma Inc. (the “Company” or “CanVeer”), a preclinical biopharmaceutical company developing therapies for severe respiratory diseases with high unmet medical need, is pleased to announce the filing of its international Patent Cooperation Treaty (PCT) patent application of its investigational new drug candidate AlveoShield™, marking an important milestone in strengthening the Company’s global intellectual property […]
Mississauga, Canada
CanVeer Biopharma Inc. (the “Company” or “CanVeer”), a preclinical biopharmaceutical company developing therapies for severe respiratory diseases with high unmet medical need, is pleased to announce the filing of its international Patent Cooperation Treaty (PCT) patent application of its investigational new drug candidate AlveoShield™, marking an important milestone in strengthening the Company’s global intellectual property strategy for chronic respiratory conditions
The patent application, titled “METHODS AND COMPOSITIONS FOR PREVENTING, ATTENUATING OR TREATING LUNG DISEASES AND/OR INJURY,” builds upon CanVeer’s previously filed United States provisional patent and supports the continued development of the Company’s proprietary therapeutic platform, including its lead investigational program, AlveoShield™.
The PCT application was formally submitted through the Canadian Intellectual Property Office acting as the Canadian Receiving Office. The filing establishes an international priority date and provides a strategic framework for pursuing patent protection across more than 150 participating jurisdictions worldwide, supporting CanVeer’s long-term commercialization and partnering strategy. The intellectual property underlying the application is owned by CanVeer.
CanVeer’s lead therapeutic candidate, AlveoShield™, is currently being developed as a potential first-in-class disease modifying therapy for bronchopulmonary dysplasia (BPD), a severe respiratory condition affecting preterm newborns who require oxygen support at birth to survive. Currently there are no approved disease-modifying therapies for BPD in the clinic, putting over 150,000 preterm newborns annually in North America at risk of developing BPD, and suffering lifelong severe respiratory consequences.
CanVeer is also evaluating formulation and pulmonary delivery strategies to support future clinical translation and commercialization of AlveoShield™.
While the Company’s initial development focus is neonatal respiratory disease, the broader patent strategy strengthens potential future applications in additional respiratory conditions involving lung injury and inflammation.
IPON Support Strengthens Global IP Strategy
CanVeer was previously accepted into the Intellectual Property Ontario (IPON) program, which enables Ontario companies advancing intellectual property protection and commercialization strategies. Under the program, CanVeer is eligible to receive up to CAD $300,000 in lifetime support, operating under an 80% provincial cost-sharing model for eligible intellectual property activities.
The support is positioned to help offset costs associated with international patent prosecution, freedom-to-operate analyses, competitive IP landscaping, and commercialization-related legal activities.
Management Commentary
“The filing of our international PCT application represents an important milestone in CanVeer’s commercial strategy as we continue advancing AlveoShield™ towards the clinic,” said Sherif Louis, CEO of CanVeer. “Establishing international priority rights empowers our long-term objective of protecting the program and assures global market potential and exclusivity.”
“Support from IPON has played an important role in accelerating the development of our global intellectual property strategy,” said Behzad Yeganeh, CSO of CanVeer and co-inventor of the technology. “Combined with the guidance of our IP Counsel, SMART & BIGGAR, this PCT filing further strengthens the patent foundation supporting the future clinical and commercial development of AlveoShield™ and our broader respiratory therapeutic platform.”
About CanVeer Biopharma Inc.
CanVeer Biopharma is a privately owned pre-clinical biopharmaceutical company advancing innovative therapeutics for chronic diseases with high unmet medical needs. The Company’s lead program, AlveoShield™, is being developed as a potential therapy for bronchopulmonary dysplasia (BPD), a severe chronic respiratory condition affecting preterm infants who require assisted ventilation at birth. Currently, there are no approved disease-modifying therapies for BPD. AlveoShield™ is designed to target biological pathways underlying lung injury to support normal lung development. For more information, please visit www.canveer.com.
For further information, please contact:
Sherif Louis
Chief Executive Officer
CanVeer Biopharma Inc.
647-293-6555
[email protected]
www.canveer.com
Cautionary Note Regarding Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking information is often identified by terms such as “will,” “intends,” “potential,” “aiming,” “planned,” or similar expressions and includes statements regarding the clinical efficacy and commercial viability of AlveoShield™, anticipated development and IP filing timelines, regulatory milestones, and the benefits of the IPON program. These statements are based on current expectations and are subject to significant risks, uncertainties, and assumptions that could cause actual results to differ materially. These include risks inherent in drug development, regulatory processes, intellectual property prosecution, and the availability of program funding. Readers are cautioned not to place undue reliance on forward-looking information. The Company undertakes no obligation to update forward-looking statements except as required by law. This release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of CanVeer Biopharma Inc.
Uncategorized
SP Prestige Expands Global Wealth Management Solutions for International Investors
DENVER, ColGlobal financial markets continue to create new opportunities for investors seeking diversified portfolios and long-term wealth preservation. As capital increasingly moves across international markets, investors are looking for investment platforms that combine professional financial expertise, digital innovation, and access to global opportunities. SP Prestige, the global investment platform developed by SilverPeak Strategic Capital LLC, is […]
DENVER, Col
Global financial markets continue to create new opportunities for investors seeking diversified portfolios and long-term wealth preservation. As capital increasingly moves across international markets, investors are looking for investment platforms that combine professional financial expertise, digital innovation, and access to global opportunities.

SP Prestige, the global investment platform developed by SilverPeak Strategic Capital LLC, is designed to meet these evolving needs by providing comprehensive wealth management solutions for individual, corporate, and institutional investors worldwide.
Rather than focusing on a single asset class or geographic market, SP Prestige promotes diversified investment strategies across multiple industries, regions, and market sectors. This approach helps investors manage changing economic conditions while building portfolios aligned with their long-term financial objectives.
Supported by a team of experienced professionals specializing in wealth management, capital markets, investment research, financial planning, and portfolio analysis, SP Prestige combines disciplined investment practices with market insights to help clients make informed financial decisions.

As investor expectations continue to evolve, digital accessibility has become an essential part of modern wealth management. SP Prestige integrates portfolio management, market intelligence, investment tools, and online account services into a unified digital experience, allowing clients to monitor investments, access research, and stay connected to financial markets from anywhere in the world. The platform combines advanced technology with professional advisory services to deliver a balanced investment experience.
Reliable market information has become increasingly valuable in today’s rapidly changing investment environment. Through research publications, educational resources, market commentary, and ongoing client communication, SP Prestige supports investors in making decisions based on long-term analysis rather than short-term market movements.
Wealth management extends beyond investment performance alone. Long-term financial planning often includes liquidity management, portfolio risk assessment, estate planning, tax efficiency, family wealth preservation, and business succession strategies. SP Prestige is designed to support these broader financial objectives by providing flexible solutions that adapt to clients’ evolving personal and business needs.

As part of its continued global growth strategy, SP Prestige continues to enhance its digital investment capabilities while expanding the range of financial services available through the platform. By combining experienced financial professionals, advanced technology, and international market access, the platform aims to provide investors with comprehensive wealth management solutions for today’s global investment environment.
Supporting its commitment to regulatory compliance and operational transparency, SilverPeak Strategic Capital LLC, the company behind SP Prestige, maintains a registration with the Financial Crimes Enforcement Network (FinCEN) as a Money Services Business (MSB). The company also has a public filing under SEC Form D in the United States, reflecting its participation in applicable regulatory reporting requirements.
About SP Prestige
SP Prestige is the global investment platform developed and operated by SilverPeak Strategic Capital LLC. The platform provides wealth management, asset management, portfolio management, market intelligence, and digital investment solutions for individual, corporate, and institutional investors.
Combining professional financial expertise with technology-driven investment services, SP Prestige is committed to helping clients build diversified portfolios, access global investment opportunities, and pursue long-term financial objectives through disciplined investment management.
Media Contact:
Mike
Email: [email protected]
Uncategorized
Investing Platform (www.investingplatform.com.au) Lists 500+ Brand-New Properties Across Three Australian Growth Corridors
SYDNEY, AustraliaInvesting Platform (www.investingplatform.com.au), the home of brand-new property in Australia, is live with more than 500 individual brand-new residential properties listed across approximately 33 developments, spanning three of the country’s most active growth corridors. The platform’s current property inventory clusters across Greater Sydney and metropolitan New South Wales, the New South Wales coastal regions of […]
SYDNEY, Australia

Investing Platform (www.investingplatform.com.au), the home of brand-new property in Australia, is live with more than 500 individual brand-new residential properties listed across approximately 33 developments, spanning three of the country’s most active growth corridors.
The platform’s current property inventory clusters across Greater Sydney and metropolitan New South Wales, the New South Wales coastal regions of the Illawarra and Central Coast, and the Melbourne growth corridor in Victoria. Listed developments include locations across Parramatta, Macquarie Park and the Sydney metropolitan area, the Illawarra centres of Wollongong, Shell Cove and Kiama, and Victoria’s expanding outer-Melbourne corridor including Clyde North, Tarneit, Werribee, Craigieburn and Officer.
“The stock is where the growth is,” said Adam Newman, who co-founded Investing Platform with Adnan Tanveer. “Investors want to see brand-new property in the corridors that are actually being built out and moved into, not a thin catalogue. More than 500 brand-new properties live across three genuine growth corridors is what the home of brand-new property looks like on day one.”
Investing Platform operates as an aggregator service and positions itself as the home of brand-new property, bringing new-build residential property together with private equity and income-producing fund opportunities in one place. Brand-new property listings are open to all investors. The platform does not hold client funds, and property
listings are provided as referrals to third-party aggregators and developers.
The launch inventory sits in the brand-new residential property category at a time when investor demand for new builds is being shaped by lender policy, with Australia’s major banks restricting negative gearing treatment to new builds over recent weeks.
“We built this to be useful on the day it opened,” Newman said. “One place for brand-new property, real inventory, in the markets people are actually buying into.”
Investing Platform is live now at www.investingplatform.com.au.
About Investing Platform
Investing Platform, the home of brand-new property in Australia, is an online marketplace that aggregates new-build residential property, private equity and income-producing fund opportunities in one place. Brand-new property is open to all investors; fund and private equity opportunities are available to qualifying wholesale and sophisticated investors. The platform operates as an aggregator service and does not hold client funds. Investing Platform was co-founded by Adnan Tanveer and Adam Newman.
About Adam Newman
Adam Newman is co-founder of Investing Platform, the home of brand-new property in Australia. He works alongside co-founder Adnan Tanveer to bring new-build residential property, private equity and income-producing fund opportunities onto a single marketplace.
Media Contact:
PR Team for Investing Platform
Email: [email protected]
Uncategorized
Sequentum Cloud Wins 2026 CODiE Award for Best No-Code/Low-Code Platform
New York, NYSequentum Cloud wins 2026 CODiE Award for Best No-Code/Low-Code Platform in the Developer & AI Technology track, marking its second consecutive year as a finalist and first win. The award recognizes Agent Builder and the broader Sequentum Cloud platform for AI-powered web data collection. sequentum.com/cloud
New York, NY
Sequentum Cloud has won the 2026 CODiE Award for Best No-Code/Low-Code Platform in the Developer & AI Technology track, announced on July 15, 2026 (https://codieawards.com/winners).
The win follows two consecutive years as a CODiE Finalist. In 2025, Sequentum Cloud was recognized in the Best Financial & Market Data Solution category. This year’s win in the Developer & AI Technology track reflects the platform’s expanding reach. Sequentum continues to serve financial institutions, government agencies, and global enterprises while growing adoption among developers and technical teams building AI-powered data pipelines across industries.
“This is a proud moment for the entire Sequentum team,” said Tony Jaensch, CEO and Founder. “Sequentum is celebrating 18 years and the 8th anniversary of our Center of Excellence in India, and winning the CODiE is the perfect milestone to mark how far we’ve come. We built Agent Builder on a simple idea: enterprise teams should be able to describe the data they need in plain language and get a production-grade, auditable agent in minutes. This win tells us the industry sees the same opportunity we do.”
The nomination is based on Sequentum Cloud, originally launched in October 2024, and its latest capability, Agent Builder, launched in May 2026, which turns natural language prompts into deterministic, versioned web data agents deployed via MCP, API, or the Cloud UI with full governance and auditability.
Agent Builder builds on a broader Sequentum Cloud feature set:
AI Magic Wand — AI augmented web data extraction to accelerate agent configuration
Visual Editor — deep customization without code
Web Unblocker — anti-bot resistance with user-controlled compliance settings
Command Templates — reusable, standardized logic for team-scale development
MCP Integration — direct access to Sequentum agents from Cursor, Claude, and ChatGPT
SOC 2 Type 2 Certification — enterprise security and compliance built in.
Unlike AI-only scraping tools that operate as a black box, no AI is used at run time. Every agent run is fully logged, version-controlled, and auditable, meeting the governance standards of financial institutions, government agencies, and global enterprises. Agent Builder is part of a broader Sequentum Cloud platform that includes AI Magic Wand for accelerated agent configuration, a Visual Editor for deep customization without code, Web Unblocker for compliant anti-bot resistance, Command Templates for team-scale standardization, native MCP integration with Cursor, Claude, and ChatGPT, and SOC 2 Type 2 certification built in.
Beyond Data: Sequentum’s Entry into Agentic Commerce
The CODiE win recognizes Sequentum Cloud’s data extraction capabilities, but the platform’s reach now extends further. In April 2026, Sequentum launched Checkout Agent, the first enterprise-scale checkout agent for agentic commerce, integrated with Skyfire’s tokenized identity and payments network. Built on the same 18 years of browser automation infrastructure, Checkout Agent enables AI agents to transact autonomously on the open web with full governance, auditability, and compliance, extending Sequentum’s promise from “Trust in Data” to “Trust in Agents”.
For more on Checkout Agent, see our announcement: We Built the Checkout Agent That Actually Works. Here’s Why We Did It, and Who We Did It With.
Start building AI-powered web data agents today. Learn more and sign up at sequentum.com/cloud#agent-builder.
About Sequentum
Web data you can trust for the AI era. Precision, compliance, traceability, and reliability at scale.
Sequentum is the platform for AI-powered web data collection, enabling organizations to acquire trusted web data, build and govern intelligent agents, and transact securely in the emerging agentic economy. With offices in the U.S., Australia, and India, Sequentum delivers solutions — Sequentum Cloud, Sequentum Enterprise, Managed Data Services, hybrid deployments, Intelligent Agents, and Checkout Agent for agentic commerce — trusted by leading financial institutions, global enterprises, and government agencies. Get the Sequentum Edge. Learn more at sequentum.com.
Media Contact:
Elizabeth Abrams
Sequentum
Email: [email protected]
Phone: 18665946019
Website: https://www.sequentum.com/
-
Uncategorized10 months agoKirill Dmitriev: Global Investment Strategist and Architect of International Partnership
-
Uncategorized7 months agoEscape Timeshare Fees Releases Consumer Guidance on Interpreting BBB Profiles in the Timeshare Exit Industry
-
Uncategorized1 year ago
Live with Purpose Ranked #1 Show in Binge Networks’ Top 10 for July
-
Uncategorized7 months agoTreasureNFT: Partnering with BlackRock Capital for a Major Upgrade – NOVA Platform Aims to Become the World’s Largest NFT Trading Ecosystem
-
Entertainment & Sports2 years agoRachael Sage Releases Powerful Reimagined Acoustic Album, Another Side
-
Business1 year agoAivista Quant Capital CEO Dr. Smith: Tariff Policies Trigger Wrongful Sell-Off in Quality Assets, ETH Below $1,400 Severely Undervalued, Targeting Over $4,500 by Year-End
-
Business2 years agoGlobal Academic Excellence with XI TING’s Professional Tutor Team
-
Politics2 years agoMusk Claims Trump Interview Targeted by Cyber Attack
